YM155, a selective survivin inhibitor, reverses chronic hypoxic pulmonary hypertension in rats via upregulating voltage-gated potassium channels

被引：17

作者：

Fan, Zaiwen ^{[1
]}

Liu, Bo ^{[1
,2
]}

Zhang, Shuai ^{[1
,2
]}

Liu, Huiguo ^{[3
]}

Li, Yang ^{[4
]}

Wang, Dong ^{[1
]}

Liu, Ying ^{[1
]}

Li, Jian ^{[1
]}

Wang, Ning ^{[1
]}

Liu, Yi ^{[1
]}

Zhang, Bo ^{[1
]}

机构：

[1] PLA Air Force, Dept Resp Med, Gen Hosp, Beijing 100142, Peoples R China

[2] Hebei North Univ, Minist Educ, Zhangjiakou, Peoples R China

[3] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Resp Med, Wuhan 430074, Peoples R China

[4] Chinese Peoples Liberat Army Gen Hosp, Inst Geriatr Cardiol, Beijing, Peoples R China

来源：

CLINICAL AND EXPERIMENTAL HYPERTENSION | 2015年 / 37卷 / 05期

关键词：

Hypoxia; potassium channels; pulmonary hypertension; survivin; YM155; ARTERIAL SMOOTH-MUSCLE; TARGETING SURVIVIN; K+ CHANNELS; CELL-PROLIFERATION; APOPTOSIS; CANCER; VASOCONSTRICTION; ACTIVATION; MECHANISMS; SUPPRESSANT;

D O I：

10.3109/10641963.2014.987390

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

To test the hypothesis that chronic hypoxic pulmonary hypertension (CH-PH) is associated with increased survivin and decreased voltage-gated potassium (KV) channels expression in pulmonary arteries, rats were randomized as: normoxia (N); normoxia + YM155, survivin suppressor (NY); hypoxia (H); hypoxia + YM155 (HY). HY group had significantly reduced pulmonary arterial pressure, right ventricular weight and right ventricular hypertrophy compared with H group. Survivin mRNA and protein were detected in pulmonary arteries of rats with CH-PH, but not rats without CH-PH. YM155 downregulated survivin protein and mRNA. KV channel expression and activity were upregulated after YM155 treatment. Survivin may play a role in the pathogenesis of CH-PH.

引用

页码：381 / 387

页数：7

共 35 条

[1] Lessons learned from cancer may help in the treatment of pulmonary hypertension [J].

Adnot, S .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (06) :1461-1463

[2] Opinion - Survivin, cancer networks and pathway-directed drug discovery [J].

Altieri, Dario C. .

NATURE REVIEWS CANCER, 2008, 8 (01) :61-70

[3] Targeting survivin in cancer [J].

Altieri, Dario C. .

CANCER LETTERS, 2013, 332 (02) :225-228

[4] Validating survivin as a cancer therapeutic target [J].

Altieri, DC .

NATURE REVIEWS CANCER, 2003, 3 (01) :46-54

[5]

Archer SL, 2006, CURR OPIN CARDIOL, V21, P385

[6] Puerarin Induces Mitochondria-Dependent Apoptosis in Hypoxic Human Pulmonary Arterial Smooth Muscle Cells [J].

Chen, Chan ;

Chen, Chun ;

Wang, Zhiyi ;

Wang, Liangxing ;

Yang, Lehe ;

Ding, Minjiao ;

Ding, Cheng ;

Sun, Yu ;

Lin, Quan ;

Huang, Xiaoying ;

Du, Xiaohong ;

Zhao, Xiaowei ;

Wang, Chuangyi .

PLOS ONE, 2012, 7 (03)

[7] Survivin in Solid Tumors: Rationale for Development of Inhibitors [J].

Church, David N. ;

Talbot, Denis C. .

CURRENT ONCOLOGY REPORTS, 2012, 14 (02) :120-128

[8] Functional consequences of caspase activation in cardiac myocytes [J].

Communal, C ;

Sumandea, M ;

de Tombe, P ;

Narula, J ;

Solaro, RJ ;

Hajjar, RJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (09) :6252-6256

[9] Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis [J].

Dohi, T ;

Beltrami, E ;

Wall, NR ;

Plescia, J ;

Altieri, DC .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (08) :1117-1127

[10] The role of mitochondria in pulmonary vascular remodeling [J].

Dromparis, Peter ;

Sutendra, Gopinath ;

Michelakis, Evangelos D. .

JOURNAL OF MOLECULAR MEDICINE-JMM, 2010, 88 (10) :1003-1010

← 1 2 3 4 →